Cryo Cell International (CCEL) Non-Current Deffered Revenue (2010 - 2026)

Cryo Cell International (CCEL) has 17 years of Non-Current Deffered Revenue data on file, last reported at $52.1 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $52.1 million, up 9.15% year-over-year; the trailing twelve-month figure through Feb 2026 was $52.1 million (up 9.15% YoY), and the FY2025 annual result was $51.0 million, up 9.49% from the prior year.
• Non-Current Deffered Revenue improved to $52.1 million in Q1 2026 per CCEL's latest filing, from $51.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $52.1 million in Q1 2026 and troughed at $32.2 million in Q1 2022.
• A 5-year average of $42.4 million and a median of $42.6 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2023 and 2026: Non-Current Deffered Revenue increased 15.84% in 2023, then climbed 9.15% in 2026.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $36.0 million in 2022, then grew by 14.41% to $41.2 million in 2023, then rose by 13.04% to $46.6 million in 2024, then grew by 9.49% to $51.0 million in 2025, then increased by 2.21% to $52.1 million in 2026.
• Business Quant data shows CCEL's Non-Current Deffered Revenue at $52.1 million in Q1 2026, $51.0 million in Q4 2025, and $49.8 million in Q3 2025.